Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges
Antibody-drug conjugates (ADCs) offer selective delivery of potent cytotoxic payloads to tumour-associated antigens and are therefore attractive candidates for biomarker-informed treatment development. However, antigen heterogeneity, payload resistance…